BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25801911)

  • 21. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
    Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
    Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
    Shi X; Lan X; Chen X; Zhao C; Li X; Liu S; Huang H; Liu N; Zang D; Liao Y; Zhang P; Wang X; Liu J
    Sci Rep; 2015 Apr; 5():9694. PubMed ID: 25853502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CUL4B regulates autophagy via JNK signaling in diffuse large B-cell lymphoma.
    Li Y; Zhou X; Zhang Y; Yang J; Xu Y; Zhao Y; Wang X
    Cell Cycle; 2019 Feb; 18(4):379-394. PubMed ID: 30612524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma.
    Zhou X; Fang X; Jiang Y; Geng L; Li X; Li Y; Lu K; Li P; Lv X; Wang X
    J Hematol Oncol; 2017 Feb; 10(1):37. PubMed ID: 28153033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
    Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway.
    Chang S; Li B; Xie Y; Wang Y; Xu Z; Jin S; Yu D; Wang H; Lu Y; Zhang Y; Ma R; Huang C; Lai W; Wu X; Zhu W; Shi J
    Neoplasia; 2022 Jan; 24(1):50-61. PubMed ID: 34890905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.
    Dubanet L; Bentayeb H; Petit B; Olivrie A; Saada S; de la Cruz-Morcillo MA; Lalloué F; Gourin MP; Bordessoule D; Faumont N; Delage-Corre M; Fauchais AL; Jauberteau MO; Troutaud D
    Br J Cancer; 2015 Sep; 113(6):934-44. PubMed ID: 26284337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
    Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
    Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway.
    Hu T; Gao Y
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32010942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma.
    Camicia R; Bachmann SB; Winkler HC; Beer M; Tinguely M; Haralambieva E; Hassa PO
    J Cell Sci; 2013 May; 126(Pt 9):1969-80. PubMed ID: 23487038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
    Wang WG; Jiang XN; Sheng D; Sun CB; Lee J; Zhou XY; Li XQ
    Lab Invest; 2019 Oct; 99(10):1418-1427. PubMed ID: 31197205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
    Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The novel kinesin spindle protein (KSP) inhibitor SB-743921 exhibits marked activity in in vivo and in vitro models of aggressive large B-cell lymphoma.
    Bongero D; Paoluzzi L; Marchi E; Zullo KM; Neisa R; Mao Y; Escandon R; Wood K; O'Connor OA
    Leuk Lymphoma; 2015; 56(10):2945-52. PubMed ID: 25860245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
    Seda V; Mraz M
    Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) induces apoptosis of human diffuse large B-cell lymphoma cells through a peroxisome proliferator-activated receptor gamma-independent pathway.
    Ray DM; Morse KM; Hilchey SP; Garcia TM; Felgar RE; Maggirwar SB; Phipps RP; Bernstein SH
    Exp Hematol; 2006 Sep; 34(9):1202-11. PubMed ID: 16939813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.
    Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H
    Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.
    Chapuy B; Cheng H; Watahiki A; Ducar MD; Tan Y; Chen L; Roemer MG; Ouyang J; Christie AL; Zhang L; Gusenleitner D; Abo RP; Farinha P; von Bonin F; Thorner AR; Sun HH; Gascoyne RD; Pinkus GS; van Hummelen P; Wulf GG; Aster JC; Weinstock DM; Monti S; Rodig SJ; Wang Y; Shipp MA
    Blood; 2016 May; 127(18):2203-13. PubMed ID: 26773040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
    Li L; Zhang J; Chen J; Xu-Monette ZY; Miao Y; Xiao M; Young KH; Wang S; Medeiros LJ; Wang M; Ford RJ; Pham LV
    Blood; 2018 Oct; 132(17):1805-1817. PubMed ID: 30209121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma.
    Chen JL; Chu PY; Huang CT; Huang TT; Wang WL; Lee YH; Chang YY; Dai MS; Shiau CW; Liu CY
    Mol Med; 2022 Aug; 28(1):93. PubMed ID: 35941532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.